Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

KEYNOTE-866 : A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Urinary System<br/>CancersCancer LocationUrinary System
Cancers

Systemic therapy | Urinary systemBladder

Trial Overview Read MoreRead more

This phase III trial is evaluating the effectiveness of administering a targeted therapy (Pembrolizumab) in combination with chemotherapy drugs (Gemcitabine and Cisplantin) before surgery to treat patients with bladder cancer.
 

This trial is treating patients with Bladder cancer.

This is a systemic therapy.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

  • NCT03924856
  • 3475-866, 2018-003808-39, MK-3475-866, 194870

Scientific Title

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer

Commercial Sponsor

Merck

Summary

Patients eligible to participate in this trial will receive 4 pre-operative cycles of gemcitabine, cisplatin and pembrolizumab or a placebo. After surgery, 13 cycles of pembrolizumab or placebo will be received.

Recruiting Hospitals Read MoreRead more

Peninsula Health
Frankston
Ms Judi Clarke
jclarke@phcn.vic.gov.au
03 9784 8301

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next